#United States #Burlington #Jerome Adams #Consano Bio #C-1101

Consano Bio's Scientific Advisory Board: A Game Changer for Chronic Sciatica Therapy

Consano Bio, a biotechnology startup focused on address serious orthopedic pain conditions, has recently showcased the pivotal role of its Scientific Advisory Board (SAB) as they forge ahead in developing C-1101, an innovative and potential first-in-class non-opioid therapy designed to treat chronic lumbosacral radiculopathy, commonly known as chronic sciatica. This disease-modifying therapy could usher in a new era of pain management for patients seeking alternatives to opioid medications.

The Scientific Advisory Board is composed of seasoned experts across diverse fields including pain medicine, regulatory strategy, biologics manufacturing, and hematological research. Their extensive knowledge will help guide the clinical strategy of C-1101 as it progresses through various clinical phases. Among the board members are highly respected figures like Jerome Adams, M.D., MPH, the former U.S. Surgeon General, and Christopher Centeno, M.D., who is a leading name in interventional orthopedics. Their involvement not only enhances the credibility of the endeavor but also underscores the urgent need for effective solutions to combat chronic pain.

According to Andrew Hall, CEO of Consano Bio, chronic sciatica is a significant unmet medical need in the United States, necessitating a combination of scientific innovation and disciplined execution. With the assistance of their Scientific Advisory Board and external advisors, the company is poised to navigate the complex landscape of clinical trials and regulatory requirements. Hall emphasizes how pivotal this leadership input is to the project's success, particularly for patients who have limited options today.

The visionary Jerome Adams underscored a common frustration in the management of chronic pain—patients often resort to temporary symptom relief rather than addressing the underlying issues. He points out that there is a desperate need for non-opioid solutions that prioritize long-term patient outcomes, highlighting how Consano's focus with C-1101 aligns with this critical requirement.

In addition to Adams, the Scientific Advisory Board also features myriad experts:

• - Susan Stewart, JD, LL.M, RAC, FRAPS: An authority in regulatory affairs with over 35 years of experience in the drug and biologic sectors.
• - Mihir Kamdar, MD: A Pain Medicine specialist at Massachusetts General Hospital and a Harvard Medical School faculty member.
• - Ralph Vassallo, MD: Executive Vice President at Vitalant, who has extensive experience in transfusion medicine and therapeutic science.
• - Li Malmberg, PhD: A seasoned expert with nearly three decades of experience focused on biologics development and manufacturing.

Dr. Kamdar expressed his enthusiasm toward being part of Consano's mission, citing the pressing need for improved treatments in lumbosacral radiculopathy. He and his fellow board members are eager to leverage their collective insights to drive forward this essential innovation that could reconcile the gap in chronic pain treatment.

Understanding Chronic Lumbosacral Radiculopathy

Chronic lumbosacral radiculopathy (or chronic sciatica) is a debilitating condition resulting from damage to or irritation of spinal nerve roots within the lower back. Patients typically experience radiating pain, numbness, and muscle weakness that can extend down into the legs. Its presence is widely acknowledged yet lacks FDA-approved pharmacological treatments, despite its prevalence and significant societal impacts.

The C-1101 Initiative

C-1101 is heralded as Consano Bio’s groundbreaking investigational clinical candidate. As a novel, platelet-derived multi-protein biologic therapeutic, it aspires to not only treat pain but also modulate inflammation and promote cellular repair at injury sites. This therapy is intended to deliver an optimized mix of cytokines, growth factors, and matrix proteins via epidural injection, strategically providing supraphysiologic concentrations to the sites of nerve damage, thereby signaling natural healing pathways.

About Consano Bio

Founded in 2023 and situated in the Greater Boston area, Consano Bio is on a mission to revolutionize the treatment landscape for painful orthopedic conditions through a new class of multi-protein biologic therapeutics. More information can be found at Consano Bio's website.

As the field of pain management continues to evolve, the contributions of Consano Bio's Scientific Advisory Board are set to shape the future of chronic pain treatment, potentially providing a beacon of hope for the millions afflicted by persistent pain conditions.